2,516 Shares in Quest Diagnostics Incorporated $DGX Purchased by Gateway Wealth Partners LLC

Gateway Wealth Partners LLC acquired a new position in Quest Diagnostics Incorporated (NYSE:DGX) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 2,516 shares of the medical research company’s stock, valued at approximately $493,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in DGX. Moneta Group Investment Advisors LLC increased its stake in shares of Quest Diagnostics by 3.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 1,387 shares of the medical research company’s stock worth $241,000 after purchasing an additional 50 shares during the last quarter. HB Wealth Management LLC raised its holdings in shares of Quest Diagnostics by 0.5% in the 4th quarter. HB Wealth Management LLC now owns 11,292 shares of the medical research company’s stock worth $1,960,000 after purchasing an additional 58 shares during the period. Ossiam lifted its stake in Quest Diagnostics by 6.1% in the third quarter. Ossiam now owns 1,059 shares of the medical research company’s stock valued at $202,000 after purchasing an additional 61 shares during the last quarter. Independent Advisor Alliance lifted its stake in Quest Diagnostics by 1.6% in the fourth quarter. Independent Advisor Alliance now owns 4,298 shares of the medical research company’s stock valued at $746,000 after purchasing an additional 66 shares during the last quarter. Finally, Checchi Capital Advisers LLC grew its holdings in Quest Diagnostics by 5.6% during the fourth quarter. Checchi Capital Advisers LLC now owns 1,326 shares of the medical research company’s stock valued at $230,000 after purchasing an additional 70 shares during the period. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

Quest Diagnostics Stock Down 0.5%

Quest Diagnostics stock opened at $233.21 on Friday. Quest Diagnostics Incorporated has a 1-year low of $166.76 and a 1-year high of $240.13. The firm has a market capitalization of $25.74 billion, a price-to-earnings ratio of 24.76, a P/E/G ratio of 2.16 and a beta of 0.58. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.72. The firm has a 50 day simple moving average of $207.36 and a 200 day simple moving average of $199.58.

Quest Diagnostics (NYSE:DGX) last issued its earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.82 by $0.30. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The business had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $2.97 billion. During the same quarter in the previous year, the firm posted $2.62 EPS. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, analysts predict that Quest Diagnostics Incorporated will post 11.15 earnings per share for the current year.

Quest Diagnostics Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, July 22nd. Investors of record on Wednesday, July 8th were issued a dividend of $0.86 per share. The ex-dividend date of this dividend was Wednesday, July 8th. This represents a $3.44 dividend on an annualized basis and a yield of 1.5%. Quest Diagnostics’s dividend payout ratio is 36.52%.

Analysts Set New Price Targets

A number of research firms have issued reports on DGX. Truist Financial raised their target price on Quest Diagnostics from $225.00 to $250.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Barclays upped their price target on Quest Diagnostics from $230.00 to $250.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Jefferies Financial Group reiterated a “buy” rating and set a $245.00 price target on shares of Quest Diagnostics in a research note on Thursday, July 23rd. Mizuho lifted their price objective on Quest Diagnostics from $235.00 to $260.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Finally, UBS Group boosted their price objective on Quest Diagnostics from $220.00 to $232.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Six equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $235.31.

Insider Buying and Selling

In other Quest Diagnostics news, CEO J. E. Davis sold 10,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $194.14, for a total value of $1,941,400.00. Following the completion of the transaction, the chief executive officer owned 132,423 shares in the company, valued at $25,708,601.22. This trade represents a 7.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of Quest Diagnostics stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $200.00, for a total value of $1,629,400.00. Following the transaction, the senior vice president directly owned 13,510 shares of the company’s stock, valued at $2,702,000. The trade was a 37.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 19,747 shares of company stock valued at $3,947,088. Corporate insiders own 0.88% of the company’s stock.

Quest Diagnostics Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.